Sema4a-KO Mouse
Common Name
Sema4a-KO
제품 ID
S-KO-20337
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-20351-Sema4a-B6J-VB
상태
이 마우스 계통을 논문에서 사용할 경우, “Sema4a-KO Mouse (카탈로그 번호 S-KO-20337)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Sema4a-KO
품종 계통계통 ID
KOCMP-20351-Sema4a-B6J-VB
유전자명
제품 ID
S-KO-20337
유전자 별칭
SemB, Semab
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 3
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000029700
NCBI 전사체 ID
NM_013658
타겟 영역
Exon 7~9
유효 영역 크기
~2.0 kb
유전자 연구 개요
Sema4a, a member of the semaphorin family, was initially recognized as an axon guidance factor in the nervous system. It is preferentially expressed on immune cells and has been shown to play crucial roles in immune function, angiogenesis, and cell-cell interactions. Sema4a has 4 types of receptors: Plexin D family, Plexin B family, Tim-2, and Nrp-1 [3].
In prostate cancer, Sema4a was highly expressed in tissues, correlated with Gleason scores and distant metastasis. Genetic depletion of Sema4a prevented lung metastasis in PCa xenograft models, indicating its role in promoting cancer invasion through inducing Epithelial-mesenchymal transition (EMT) of PCa cells and establishing a positive loop with IL-10 in stromal cells [1].
In multiple sclerosis (MS), approximately one-third of patients with high Sema4a levels were unresponsive to IFN-β treatment. In an animal model of MS (EAE), administration of Sema4A concurrently with IFN-β abrogated the efficacy of IFN-β, as Sema4a promoted Th1 and Th17 differentiation and increased adhesive activation of T cells to endothelial cells [2,6]. In the effector phase of adoptively transferred EAE model, Sema4a-deficient (Sema4a KO) recipient mice receiving Th17-skewed WT myelin oligodendrocyte glycoprotein (MOG)-specific encephalitogenic T cells showed a reduced clinical score, suggesting Sema4a is involved in accelerating Th17-cell-mediated neuroinflammation in the effector phase [4].
In non-small cell lung cancer (NSCLC), Sema4a-positive tumors responded better to anti-programmed cell death 1 (PD-1) antibody. Sema4a promoted cytotoxicity and proliferation of tumor-specific CD8+ T cells in murine models, potentially being a biomarker for predicting and promoting ICI efficacy [5].
In conclusion, Sema4a plays essential roles in immune function, angiogenesis, and cancer progression. Studies using Sema4a KO mouse models have revealed its significance in prostate cancer invasion, MS pathogenesis, and the response to certain cancer immunotherapies. These findings contribute to a better understanding of the underlying mechanisms of these diseases and may provide potential therapeutic targets.
References:
1. Liu, Xiao, Tan, Weiwei, Wang, Weiqi, Wang, Lin, Zhou, Wei. 2023. SEMA4A promotes prostate cancer invasion: involvement of tumor microenvironment. In Journal of Cancer, 14, 2633-2643. doi:10.7150/jca.86739. https://pubmed.ncbi.nlm.nih.gov/37779872/
2. Nakatsuji, Yuji. . [Sema4A as a biomarker predicting responsiveness to IFN β treatment]. In Rinsho shinkeigaku = Clinical neurology, 54, 972-4. doi:. https://pubmed.ncbi.nlm.nih.gov/25519959/
3. Ito, Daisuke, Kumanogoh, Atsushi. 2016. The role of Sema4A in angiogenesis, immune responses, carcinogenesis, and retinal systems. In Cell adhesion & migration, 10, 692-699. doi:. https://pubmed.ncbi.nlm.nih.gov/27736304/
4. Koda, Toru, Namba, Akiko, Kinoshita, Makoto, Mochizuki, Hideki, Okuno, Tatsusada. 2020. Sema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase. In Journal of neuroinflammation, 17, 82. doi:10.1186/s12974-020-01757-w. https://pubmed.ncbi.nlm.nih.gov/32169103/
5. Naito, Yujiro, Koyama, Shohei, Masuhiro, Kentaro, Takeda, Yoshito, Kumanogoh, Atsushi. 2023. Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8+ T cell cytotoxicity and proliferation. In Science advances, 9, eade0718. doi:10.1126/sciadv.ade0718. https://pubmed.ncbi.nlm.nih.gov/37205755/
6. Koda, Toru, Okuno, Tatsusada, Takata, Kazushiro, Kumanogoh, Atsushi, Nakatsuji, Yuji. 2014. Sema4A inhibits the therapeutic effect of IFN-β in EAE. In Journal of neuroimmunology, 268, 43-9. doi:10.1016/j.jneuroim.2013.12.014. https://pubmed.ncbi.nlm.nih.gov/24439904/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
